Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide-based Therapies. This report contains market size and forecasts of Oligonucleotide-based Therapies in global, including the following market information:
Global Oligonucleotide-based Therapies Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Oligonucleotide-based Therapies market was valued at US$ 3784.6 million in 2022 and is projected to reach US$ 7626 million by 2029, at a CAGR of 10.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
We surveyed the Oligonucleotide-based Therapies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oligonucleotide-based Therapies Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Oligonucleotide-based Therapies Market Segment Percentages, by Type, 2022 (%)
Antisense Oligonucleotide
Aptamer
Other
Global Oligonucleotide-based Therapies Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Oligonucleotide-based Therapies Market Segment Percentages, by Application, 2022 (%)
Neuromuscular Diseases
Hepatic VOD
Other
Global Oligonucleotide-based Therapies Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Oligonucleotide-based Therapies Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oligonucleotide-based Therapies revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Oligonucleotide-based Therapies revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oligonucleotide-based Therapies, market overview.
Chapter 2: Global Oligonucleotide-based Therapies market size in revenue.
Chapter 3: Detailed analysis of Oligonucleotide-based Therapies company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oligonucleotide-based Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Oligonucleotide-based Therapies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oligonucleotide-based Therapies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oligonucleotide-based Therapies Overall Market Size
2.1 Global Oligonucleotide-based Therapies Market Size: 2022 VS 2030
2.2 Global Oligonucleotide-based Therapies Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oligonucleotide-based Therapies Players in Global Market
3.2 Top Global Oligonucleotide-based Therapies Companies Ranked by Revenue
3.3 Global Oligonucleotide-based Therapies Revenue by Companies
3.4 Top 3 and Top 5 Oligonucleotide-based Therapies Companies in Global Market, by Revenue in 2022
3.5 Global Companies Oligonucleotide-based Therapies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oligonucleotide-based Therapies Players in Global Market
3.6.1 List of Global Tier 1 Oligonucleotide-based Therapies Companies
3.6.2 List of Global Tier 2 and Tier 3 Oligonucleotide-based Therapies Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Oligonucleotide-based Therapies Market Size Markets, 2022 & 2030
4.1.2 Antisense Oligonucleotide
4.1.3 Aptamer
4.1.4 Other
4.2 By Type - Global Oligonucleotide-based Therapies Revenue & Forecasts
4.2.1 By Type - Global Oligonucleotide-based Therapies Revenue, 2018-2023
4.2.2 By Type - Global Oligonucleotide-based Therapies Revenue, 2024-2030
4.2.3 By Type - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oligonucleotide-based Therapies Market Size, 2022 & 2030
5.1.2 Neuromuscular Diseases
5.1.3 Hepatic VOD
5.1.4 Other
5.2 By Application - Global Oligonucleotide-based Therapies Revenue & Forecasts
5.2.1 By Application - Global Oligonucleotide-based Therapies Revenue, 2018-2023
5.2.2 By Application - Global Oligonucleotide-based Therapies Revenue, 2024-2030
5.2.3 By Application - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Oligonucleotide-based Therapies Market Size, 2022 & 2030
6.2 By Region - Global Oligonucleotide-based Therapies Revenue & Forecasts
6.2.1 By Region - Global Oligonucleotide-based Therapies Revenue, 2018-2023
6.2.2 By Region - Global Oligonucleotide-based Therapies Revenue, 2024-2030
6.2.3 By Region - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Oligonucleotide-based Therapies Revenue, 2018-2030
6.3.2 US Oligonucleotide-based Therapies Market Size, 2018-2030
6.3.3 Canada Oligonucleotide-based Therapies Market Size, 2018-2030
6.3.4 Mexico Oligonucleotide-based Therapies Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Oligonucleotide-based Therapies Revenue, 2018-2030
6.4.2 Germany Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.3 France Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.4 U.K. Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.5 Italy Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.6 Russia Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.7 Nordic Countries Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.8 Benelux Oligonucleotide-based Therapies Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Oligonucleotide-based Therapies Revenue, 2018-2030
6.5.2 China Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.3 Japan Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.4 South Korea Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.5 Southeast Asia Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.6 India Oligonucleotide-based Therapies Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Oligonucleotide-based Therapies Revenue, 2018-2030
6.6.2 Brazil Oligonucleotide-based Therapies Market Size, 2018-2030
6.6.3 Argentina Oligonucleotide-based Therapies Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue, 2018-2030
6.7.2 Turkey Oligonucleotide-based Therapies Market Size, 2018-2030
6.7.3 Israel Oligonucleotide-based Therapies Market Size, 2018-2030
6.7.4 Saudi Arabia Oligonucleotide-based Therapies Market Size, 2018-2030
6.7.5 UAE Oligonucleotide-based Therapies Market Size, 2018-2030
7 Oligonucleotide-based Therapies Companies Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Oligonucleotide-based Therapies Major Product Offerings
7.1.4 Biogen Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Sarepta Therapeutics
7.2.1 Sarepta Therapeutics Company Summary
7.2.2 Sarepta Therapeutics Business Overview
7.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Major Product Offerings
7.2.4 Sarepta Therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.2.5 Sarepta Therapeutics Key News & Latest Developments
7.3 Jazz Pharmaceuticals
7.3.1 Jazz Pharmaceuticals Company Summary
7.3.2 Jazz Pharmaceuticals Business Overview
7.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Major Product Offerings
7.3.4 Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.3.5 Jazz Pharmaceuticals Key News & Latest Developments
7.4 Bausch & Lomb
7.4.1 Bausch & Lomb Company Summary
7.4.2 Bausch & Lomb Business Overview
7.4.3 Bausch & Lomb Oligonucleotide-based Therapies Major Product Offerings
7.4.4 Bausch & Lomb Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.4.5 Bausch & Lomb Key News & Latest Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Company Summary
7.5.2 Alnylam Pharmaceuticals Business Overview
7.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Major Product Offerings
7.5.4 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.5.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.6 Dynavax Technologies
7.6.1 Dynavax Technologies Company Summary
7.6.2 Dynavax Technologies Business Overview
7.6.3 Dynavax Technologies Oligonucleotide-based Therapies Major Product Offerings
7.6.4 Dynavax Technologies Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.6.5 Dynavax Technologies Key News & Latest Developments
7.7 Kastle therapeutics
7.7.1 Kastle therapeutics Company Summary
7.7.2 Kastle therapeutics Business Overview
7.7.3 Kastle therapeutics Oligonucleotide-based Therapies Major Product Offerings
7.7.4 Kastle therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.7.5 Kastle therapeutics Key News & Latest Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Company Summary
7.8.2 Akcea Therapeutics Business Overview
7.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Major Product Offerings
7.8.4 Akcea Therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.8.5 Akcea Therapeutics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Oligonucleotide-based Therapies Market Opportunities & Trends in Global Market
Table 2. Oligonucleotide-based Therapies Market Drivers in Global Market
Table 3. Oligonucleotide-based Therapies Market Restraints in Global Market
Table 4. Key Players of Oligonucleotide-based Therapies in Global Market
Table 5. Top Oligonucleotide-based Therapies Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Oligonucleotide-based Therapies Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Oligonucleotide-based Therapies Revenue Share by Companies, 2018-2023
Table 8. Global Companies Oligonucleotide-based Therapies Product Type
Table 9. List of Global Tier 1 Oligonucleotide-based Therapies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oligonucleotide-based Therapies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Oligonucleotide-based Therapies Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Oligonucleotide-based Therapies Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Oligonucleotide-based Therapies Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Oligonucleotide-based Therapies Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Oligonucleotide-based Therapies Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue, (US$, Mn), 2024-2030
Table 30. Biogen Company Summary
Table 31. Biogen Oligonucleotide-based Therapies Product Offerings
Table 32. Biogen Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 33. Biogen Key News & Latest Developments
Table 34. Sarepta Therapeutics Company Summary
Table 35. Sarepta Therapeutics Oligonucleotide-based Therapies Product Offerings
Table 36. Sarepta Therapeutics Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 37. Sarepta Therapeutics Key News & Latest Developments
Table 38. Jazz Pharmaceuticals Company Summary
Table 39. Jazz Pharmaceuticals Oligonucleotide-based Therapies Product Offerings
Table 40. Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 41. Jazz Pharmaceuticals Key News & Latest Developments
Table 42. Bausch & Lomb Company Summary
Table 43. Bausch & Lomb Oligonucleotide-based Therapies Product Offerings
Table 44. Bausch & Lomb Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 45. Bausch & Lomb Key News & Latest Developments
Table 46. Alnylam Pharmaceuticals Company Summary
Table 47. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Product Offerings
Table 48. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 49. Alnylam Pharmaceuticals Key News & Latest Developments
Table 50. Dynavax Technologies Company Summary
Table 51. Dynavax Technologies Oligonucleotide-based Therapies Product Offerings
Table 52. Dynavax Technologies Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 53. Dynavax Technologies Key News & Latest Developments
Table 54. Kastle therapeutics Company Summary
Table 55. Kastle therapeutics Oligonucleotide-based Therapies Product Offerings
Table 56. Kastle therapeutics Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 57. Kastle therapeutics Key News & Latest Developments
Table 58. Akcea Therapeutics Company Summary
Table 59. Akcea Therapeutics Oligonucleotide-based Therapies Product Offerings
Table 60. Akcea Therapeutics Oligonucleotide-based Therapies Revenue (US$, Mn) & (2018-2023)
Table 61. Akcea Therapeutics Key News & Latest Developments
List of Figures
Figure 1. Oligonucleotide-based Therapies Segment by Type in 2022
Figure 2. Oligonucleotide-based Therapies Segment by Application in 2022
Figure 3. Global Oligonucleotide-based Therapies Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oligonucleotide-based Therapies Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Oligonucleotide-based Therapies Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Oligonucleotide-based Therapies Revenue in 2022
Figure 8. By Type - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 9. By Application - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 10. By Type - Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 12. By Application - Global Oligonucleotide-based Therapies Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 14. By Region - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 15. By Country - North America Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 16. US Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 20. Germany Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 21. France Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 28. China Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 32. India Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 34. Brazil Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
Figure 37. Turkey Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Oligonucleotide-based Therapies Revenue, (US$, Mn), 2018-2030
Figure 41. Biogen Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Sarepta Therapeutics Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bausch & Lomb Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Dynavax Technologies Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Kastle therapeutics Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Akcea Therapeutics Oligonucleotide-based Therapies Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
